Heartland

CBD products with less than 0.0% THC

Published

1 year ago

October 15, 2019

Hemp foods containing various components of the hemp plant in their original or processed form are enjoying increasing popularity worldwide.

All over the planet more countries, governments and authorities are deregulating CBD products made from natural hemp and recognising the fact that hemp products and oils have been used by mankind for hundreds of years and thus are not ‘Novel Food’ (meaning new to humans since 1997).

Despite a very positive trend and major deregulation in North America, South America, Europe, Asia, New Zealand and other countries some countries still ban CBD products with less than 0.2% THC.

How are CBD products without THC made?

If you haven’t read this article about it, then we recommend doing so.

From a product perspective, there are two major ways to solve this.

One is to use CBD crystals instead of full spectrum CBD oil in the products. We don’t like this method for several reasons.

First of all, it’s not a natural process.

Second of all, crystal-based products are still illegal in many countries in Europe and would always be considered a Novel Food by the European Food Safety Association (EFSA), which would cause further problems for everyone.

Third, CBD products with only CBD crystals do not contain a natural and full spectrum of cannabinoids. It is proven many times in research studies that it is the combination and the presence of – if not all – then a wide range of cannabinoids and not just the CBD or the THC that creates the many positive effects of the plant and this is what is called the ‘entourage effect‘. So a product containing only CBD, but not the rest of the cannabinoids would have much less positive effects on humans and pets compared to a full spectrum product.

Our mission is to develop quality and premium products that make it easier for our customers to live a healthier lifestyle.

Fourth, if producers started to use CBD crystals in their products, many would be tempted to use CBD crystals from China and other areas, where there is absolutely no quality control and where pesticides are known to be used in hemp production.

We have a much better solution

Our R&D team has solved the challenge by developing an extraction and refinement method for taking the THC out of the full spectrum CBD oils.

Yes, you heard that right. We keep everything extracted from the hemp plant, but take away only the THC cannabinoid to level of less than 10 ppm (10 milligrams per kilogram), which makes it non-detectable in laboratories by definitions and standards of all the countries we are aware of and thus 100% legal everywhere.

It is a very costly process and has required substantial investments on our side, but it is worth all the resources invested, because we would likely be the only CBD producer with this technology and with a product offering of full spectrum CBD products with less than 0.0% THC.

We still have to work on our communication and packaging design. The objective is to ensure that every local customs officer can understand why our products are fully legal in countries, where CBD products with less than 0.2% THC are not allowed for import.

We expect to launch the THC-free products before the summer is over and will keep you informed about the developments.

This article was written by an independent and third-party author specialising in CBD, hemp and cannabis research. Any opinion, advice or recommendation expressed in the article does not reflect the opinion of Formula Swiss AG or any of our employees. We do not make any claims about any of our products and refer to our disclaimer for more information.

Comments will be approved before showing up.

Source: https://uk.formulaswiss.com/blogs/cbd-news/cbd-products-with-less-than-0-0-thc

Related Topics:cannabinoid cannabis cannabis research cbd extraction heartland hemp laboratories legal method producer product quality r&d research safety thc

Up Next

Come and see us speak: Why Adding CBD Oil to your Coffee is Pointless!

Don't Miss

2.500 mg CBD oil in hempseed or olive oil now available

Heartland

The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology

Published

1 hour ago

January 20, 2021

Republished by Plato

Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects, including memory, pain, reproduction, bone remodeling or immunity, to name a few. Unsurprisingly, given these broad physiological effects, alterations of the ECS have been found in different diseases, including cancer. In recent years, the medical use of cannabis has been approved in different countries for a variety of human conditions. However, the use of these compounds, specifically as anticancer agents, remains controversial. Studies have shown that cannabinoids do have anticancer activity in different tumor types such as breast cancer, melanoma, lymphoma and adult brain cancer. Specifically, phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) has been shown to induce apoptosis and inhibit proliferation of adult cancer cells, as well as modulate angiogenesis and metastasis. Despite increasing evidence that cannabinoids elicit antitumor effects in adult cancers, there is minimal data available on their effects in children or in pediatric cancers despite public and clinical demand for information. Here we describe a comprehensive and critical review of what is known about the effects of cannabinoids on pediatric cancers, highlight current gaps in knowledge and identify the critical issues that need addressing before considering these promising but controversial drugs for use in pediatric oncology.

Keywords: CBD; THC; cannabidiol; cannabinoid; childhood cancer; medical cannabis; pediatric oncology; Δ9-tetrahydrocannabinol.

Source: https://pubmed.ncbi.nlm.nih.gov/33466435/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zmroqAMnEquTZFTfdGx1V1gPEavo-Be3-FKTecJpOlB7LykCL&fc=20200804213506&ff=20210120135252&v=2.14.2

Heartland

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment

Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been…

Published

1 hour ago

January 20, 2021

Republished by Plato

Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results from the affinity of these compounds predominantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CB₁), type two (CB₂), and the G protein-coupled receptor 55 (GPR₅₅)) but, also, for peroxisome proliferator-activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in Cannabis sp. raw material is also expressed in their increased bioavailability and penetration through the blood-brain barrier. This review provides an overview of phytochemistry and pharmacology of compounds present in Cannabis extracts in the context of the current knowledge about their synergistic actions and the implications of clinical use in the treatment of selected diseases.

Keywords: Cannabis; multitarget; phytocannabinoids (THC and CBD); receptors; terpenes.

Source: https://pubmed.ncbi.nlm.nih.gov/33466734/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zmroqAMnEquTZFTfdGx1V1gPEavo-Be3-FKTecJpOlB7LykCL&fc=20200804213506&ff=20210120135252&v=2.14.2

Heartland

Pervasive cropland in protected areas highlight trade-offs between conservation and food security

Published

1 hour ago

January 20, 2021

Republished by Plato

. 2021 Jan 26;118(4):e2010121118.

doi: 10.1073/pnas.2010121118.

Affiliations

Item in Clipboard

Varsha Vijay et al. Proc Natl Acad Sci U S A. 2021.

. 2021 Jan 26;118(4):e2010121118.

doi: 10.1073/pnas.2010121118.

Affiliations

¹ National Socio-Environmental Synthesis Center, University of Maryland, Annapolis, MD 21401; vvijay@sesync.org.
² Department of Ecology and Evolutionary Biology and National Institute for Mathematical and Biological Synthesis, University of Tennessee, Knoxville, TN 37996.

Item in Clipboard

Abstract

Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use our global synthesis cropland dataset to quantify cropland in protected areas globally and assess their relationship to conservation aims and socio-environmental context. We estimate that cropland occupies 1.4 million km² or 6% of global protected area. Cropland occurs across all protected area management types, with 22% occurring in strictly protected areas. Cropland inside protected areas is more prevalent in countries with higher population density, lower income inequality, and with higher agricultural suitability of protected lands. While this phenomenon is dominant in midnorthern latitudes, areas of cropland in protected areas of the tropics and subtropics may present greater trade-offs due to higher levels of both biodiversity and food insecurity. Although area-based targets are prominent in biodiversity goal-setting, our results show that they can mask persistent anthropogenic land uses detrimental to native ecosystem conservation. To ensure the long-term efficacy of protected areas, post-2020 goal setting must link aims for biodiversity and human health and improve monitoring of conservation outcomes in cropland-impacted protected areas.

Keywords: CBD; area-based targets; conservation; food security; protected areas.

Conflict of interest statement

The authors declare no competing interest.

References

1. Klein Goldewijk K., Beusen A., Doelman J., Stehfest E.. New anthropogenic land use estimates for the holocene: HYDE 3.2. Earth Syst. Sci. Data. 2017;9:927–953.
1. Barrett C. B.. Measuring food insecurity. Science. 2010;327:825–828.
1. Fogel R. W.. The Escape from Hunger and Premature Death, 1700-2100: Europe, America, and the Third World. 2004.
1. Crist E., Mora C., Engelman R.. The interaction of human population, food production, and biodiversity protection. Science. 2017;356:260–264.
1. Pimm S. L., Vijay V.. Population, Agriculture, and Biodiversity: Problems and Prospects. 2020;365.